UCB’s Fintepla (fenfluramine) Receives the CHMP Recommendation for Marketing Authorization to Treat Seizures Associated with Lennox-Gastaut syndrome
- The EMA’s CHMP positive opinion was based on the safety & efficacy data from the P-III trial in 263 patients aged 2-35yrs. The EC’s final decision is expected in Q1’23
- The results showed a greater reduction in the frequency of drop seizures at a dose of 0.7/mg/kg/day & additional results of fenfluramine in the OLE part of the study showed a sustained reduction in the frequency of multiple seizure types and was well tolerated at a median treatment duration of 364 days with no cases of valvular heart disease or pulmonary arterial hypertension
- Fenfluramine was approved in the US for seizures associated with Lennox- Gastaut syndrome & in the EU, US, and Japan for seizures associated with Dravet syndrome
Ref: PRNewswire | Image: UCB
Related News:- UCB Reports P-III Open-Label Extension Study Results of Fintepla (fenfluramine) for Lennox-Gastaut Syndrome
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at [email protected].